Market Research Logo

Biocon Limited - Product Pipeline Review - 2016

Biocon Limited - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Biocon Limited - Product Pipeline Review - 2016’, provides an overview of the Biocon Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Biocon Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:*:Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Biocon Limited
  • The report provides overview of Biocon Limited including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Biocon Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Biocon Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Biocon Limited’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Biocon Limited
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Biocon Limited’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Biocon Limited Snapshot
Biocon Limited Overview
Key Facts
Biocon Limited - Research and Development Overview
Key Therapeutic Areas
Biocon Limited - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Biocon Limited - Pipeline Products Glance
Biocon Limited - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Biocon Limited - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Biocon Limited - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Biocon Limited - Drug Profiles
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bevacizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BVX-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
insulin aspart - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
insulin glargine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
insulin human - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
insulin lispro - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
insulin tregopil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
itolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugates for Oncology and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trastuzumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biocon Limited - Pipeline Analysis
Biocon Limited - Pipeline Products by Target
Biocon Limited - Pipeline Products by Route of Administration
Biocon Limited - Pipeline Products by Molecule Type
Biocon Limited - Pipeline Products by Mechanism of Action
Biocon Limited - Dormant Projects
Biocon Limited - Company Statement
Biocon Limited - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Biocon Limited, Key Facts
Biocon Limited - Pipeline by Indication, 2016
Biocon Limited - Pipeline by Stage of Development, 2016
Biocon Limited - Monotherapy Products in Pipeline, 2016
Biocon Limited - Partnered Products in Pipeline, 2016
Biocon Limited - Partnered Products/ Combination Treatment Modalities, 2016
Biocon Limited - Pre-Registration, 2016
Biocon Limited - Phase III, 2016
Biocon Limited - Phase II, 2016
Biocon Limited - Phase I, 2016
Biocon Limited - Preclinical, 2016
Biocon Limited - Pipeline by Target, 2016
Biocon Limited - Pipeline by Route of Administration, 2016
Biocon Limited - Pipeline by Molecule Type, 2016
Biocon Limited - Pipeline Products by Mechanism of Action, 2016
Biocon Limited - Dormant Developmental Projects,2016
Biocon Limited, Other Locations
Biocon Limited, Subsidiaries
List of Figures
Biocon Limited - Pipeline by Top 10 Indication, 2016
Biocon Limited - Pipeline by Stage of Development, 2016
Biocon Limited - Monotherapy Products in Pipeline, 2016
Biocon Limited - Partnered Products in Pipeline, 2016
Biocon Limited - Pipeline by Target, 2016
Biocon Limited - Pipeline by Route of Administration, 2016
Biocon Limited - Pipeline by Molecule Type, 2016
Biocon Limited - Pipeline Products by Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report